TG THERAPEUTICS INC (NASDAQ:TGTX) is a biotechnology company that fits squarely within the Mark Minervini trading methodology, combining a textbook technical uptrend with accelerating earnings and revenue growth. The stock was identified through a screen that overlays Minervini’s Trend Template conditions with a High Growth Momentum rating, making it a candidate for traders who prioritize both price strength and fundamental acceleration.
Meeting the Trend Template Criteria
The Minervini Trend Template is a checklist of eight technical rules designed to isolate stocks in a strong Stage 2 uptrend. TG Therapeutics passes every condition based on the latest data:
- Price above 150???day and 200???day moving averages: Current price of $54.87 is well above the 150???day SMA ($37.68) and the 200???day SMA ($36.40).
- 150???day and 200???day moving averages trending upward: Both are rising, confirming long???term momentum.
- 50???day moving average above both 150???day and 200???day: The 50???day SMA ($49.11) sits above both longer averages, reflecting accelerating short???term strength.
- Price at least 30% above its 52???week low: The 52???week low is $25.28; the current price is 117% above that level.
- Price within 25% of its 52???week high: The 52???week high is $59.30, so the stock is trading just 7.5% below that peak.
- Relative Strength above 70: The ChartMill Relative Strength score of 95 means TGTX outperforms 95% of all stocks.
These conditions ensure that the stock is already in an established uptrend and is not extended too far from its recent consolidation zone — a key tenet of Minervini’s approach to buying near pivot points.
High???Growth Fundamentals
Beyond the technical setup, TG Therapeutics meets the high???growth criteria that Minervini demands from his candidates. The company’s earnings and revenue are accelerating rapidly:
Earnings per share (EPS) growth:
| Period |
Growth |
| EPS 1Y (TTM) |
+170.8% |
| EPS Q2Q (last quarter vs. year ago) |
+500% |
| EPS Q2Q (quarter before) |
–6.7% (but prior two quarters showed +700% and +325%) |
| EPS 1Y (last full fiscal year) |
+257.1% |
Revenue growth:
| Period |
Growth |
| Revenue 1Y (TTM) |
+81.3% |
| Sales Q2Q (last quarter vs. year ago) |
+69.6% |
| Revenue 1Y (last full fiscal year) |
+87.3% |
Profit margins have also improved. The most recent quarterly profit margin came in at 9.7%, and the full???year margin jumped to 72.6% from just 7.1% the prior year. While earnings estimate beats have been mixed, revenue beats in two of the last four quarters show that top???line momentum is real. Minervini emphasizes that “big earnings attract big attention” – and TGTX’s triple???digit earnings growth and rising revenue are precisely the kind of fundamental catalysts that can drive institutional buying.
Technical Report Summary
The ChartMill technical analysis gives TG Therapeutics an overall technical rating of 8 out of 10 and a setup quality score of 7 out of 10. The stock’s long??? and short???term trends are both positive, and it outperforms 82% of stocks in the Biotechnology industry. The nearest support zone lies between $54.57 and $54.86, with secondary support near $52.67. Resistance is minimal above the current price, which often precedes a breakout move. For a deeper look at the full technical picture, traders can review the complete technical analysis report.
Conclusion
TG Therapeutics combines the hallmarks of a Minervini???style winner: a robust uptrend confirmed by the Trend Template, accelerating earnings and revenue growth, and a technical setup with low overhead resistance. Investors who want to systematically find other stocks matching this same methodology can explore the Minervini Trend Template and High Growth Momentum screen, which updates daily with fresh candidates. As with any strategy, risk management remains critical; the stock’s tight consolidation zone provides a clear stop???loss level, but the high???growth thesis depends on continued fundamental acceleration.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth
TG THERAPEUTICS INC (NASDAQ:TGTX) is a biotechnology company that fits squarely within the Mark Minervini trading methodology, combining a textbook technical uptrend with accelerating earnings and revenue growth. The stock was identified through a screen that overlays Minervini’s Trend Template conditions with a High Growth Momentum rating, making it a candidate for traders who prioritize both price strength and fundamental acceleration.
Meeting the Trend Template Criteria
The Minervini Trend Template is a checklist of eight technical rules designed to isolate stocks in a strong Stage 2 uptrend. TG Therapeutics passes every condition based on the latest data:
These conditions ensure that the stock is already in an established uptrend and is not extended too far from its recent consolidation zone — a key tenet of Minervini’s approach to buying near pivot points.
High???Growth Fundamentals
Beyond the technical setup, TG Therapeutics meets the high???growth criteria that Minervini demands from his candidates. The company’s earnings and revenue are accelerating rapidly:
Earnings per share (EPS) growth:
Revenue growth:
Profit margins have also improved. The most recent quarterly profit margin came in at 9.7%, and the full???year margin jumped to 72.6% from just 7.1% the prior year. While earnings estimate beats have been mixed, revenue beats in two of the last four quarters show that top???line momentum is real. Minervini emphasizes that “big earnings attract big attention” – and TGTX’s triple???digit earnings growth and rising revenue are precisely the kind of fundamental catalysts that can drive institutional buying.
Technical Report Summary
The ChartMill technical analysis gives TG Therapeutics an overall technical rating of 8 out of 10 and a setup quality score of 7 out of 10. The stock’s long??? and short???term trends are both positive, and it outperforms 82% of stocks in the Biotechnology industry. The nearest support zone lies between $54.57 and $54.86, with secondary support near $52.67. Resistance is minimal above the current price, which often precedes a breakout move. For a deeper look at the full technical picture, traders can review the complete technical analysis report.
Conclusion
TG Therapeutics combines the hallmarks of a Minervini???style winner: a robust uptrend confirmed by the Trend Template, accelerating earnings and revenue growth, and a technical setup with low overhead resistance. Investors who want to systematically find other stocks matching this same methodology can explore the Minervini Trend Template and High Growth Momentum screen, which updates daily with fresh candidates. As with any strategy, risk management remains critical; the stock’s tight consolidation zone provides a clear stop???loss level, but the high???growth thesis depends on continued fundamental acceleration.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »